Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated…
Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype antibodyVYD222 and potential future Invivyd…